Oxford Biomedica (LON:OXB) Hits New 1-Year High - What's Next?

Key Points

• Oxford Biomedica's shares reached a new 52-week high at GBX 480 ($6.49) during trading, reflecting a significant increase from a previous close of GBX 439.50 ($5.95).
• JPMorgan Chase & Co. downgraded their target price for Oxford Biomedica from GBX 490 ($6.63) to GBX 400 ($5.41) while maintaining a "neutral" rating, whereas Peel Hunt reaffirmed a "buy" rating with a target of GBX 451 ($6.10).
• Company insider Heather Preston purchased 11,389 shares at an average price of GBX 324 ($4.38), indicating confidence in the stock as insiders hold 21.17% of the company.

Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 480 ($6.49) and last traded at GBX 475 ($6.43), with a volume of 420614 shares trading hands. The stock had previously closed at GBX 439.50 ($5.95).

Analyst Ratings Changes

Several brokerages recently commented on OXB. Peel Hunt reaffirmed a "buy" rating and set a GBX 451 ($6.10) target price on shares of Oxford Biomedica in a report on Friday, August 1st. JPMorgan Chase & Co. reduced their target price on shares of Oxford Biomedica from GBX 490 ($6.63) to GBX 400 ($5.41) and set a "neutral" rating for the company in a report on Tuesday, July 15th.

Oxford Biomedica Stock Performance

The company has a market capitalization of £525.66 million, a price-to-earnings ratio of -3.67 and a beta of 1.09. The company's 50-day moving average price is GBX 369.57 and its two-hundred day moving average price is GBX 336.39. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Insider Transactions at Oxford Biomedica

In other Oxford Biomedica news, insider Heather Preston bought 11,389 shares of Oxford Biomedica stock in a transaction dated Tuesday, June 17th. The stock was purchased at an average price of GBX 324 ($4.38) per share, for a total transaction of £36,900.36 ($49,926.07). Company insiders own 21.17% of the company's stock.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.